A Review Of Corilagin
123). It's notable that GLS2 is tumorigenic in breast cancer124, and its expression could compensate for lack of Gls in MYC-induced mouse liver tumours40. This implies that GLS2 could confer resistance to GLS1-certain inhibitors, including the allosteric inhibitor BPTES or CB-839, which resistance could possibly be hypothetically prevented by using